Clinical Trial Manager (9-Month Contract)
CRISPR Therapeutics
Summary
The Clinical Trial Manager will oversee the execution and management of clinical trials to ensure they meet study objectives and timelines. They are responsible for coordinating with internal teams and external vendors to maintain high standards of data quality and regulatory compliance.
Job description
Job Description
The Clinical Trial Manager will oversee the execution and management of clinical trials to ensure they meet study objectives and timelines. They are responsible for coordinating with internal teams and external vendors to maintain high standards of data quality and regulatory compliance.
Requirements
- Significant experience in clinical trial management within the pharmaceutical or biotechnology industry
- Strong understanding of GCP guidelines
- Strong understanding of clinical operations processes
Company overview
CRISPR Therapeutics AG is a pioneering Swiss-American biotechnology company founded in 2013 that specializes in developing transformative gene-based medicines using the revolutionary CRISPR/Cas9 gene editing platform. Headquartered in Zug, Switzerland with major R&D operations in Boston, Massachusetts and San Francisco, California, the company was co-founded by Nobel Prize winner Emmanuelle Charpentier and represents one of the first commercial entities to harness CRISPR technology for therapeutic applications. CRISPR Therapeutics achieved a historic milestone in December 2023 with the FDA approval of CASGEVY® (exagamglogene autotemcel), the world's first CRISPR-based therapy for treating sickle cell disease and transfusion-dependent beta thalassemia. The company maintains a diverse pipeline targeting hemoglobinopathies, oncology, regenerative medicine, cardiovascular diseases, autoimmune disorders, and rare genetic conditions. Through strategic partnerships with industry leaders like Vertex Pharmaceuticals and Bayer, CRISPR Therapeutics continues to advance its innovative platform, employing approximately 400 professionals globally and maintaining a strong financial position with over $1.8 billion in cash and marketable securities as of 2025.